Trials / Not Yet Recruiting
Not Yet RecruitingNCT06797479
Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (estimated)
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Quantification of anti PD-1 mAbs in cancer patients is extremely important to monitor pharmacokinetics and effectiveness of immunotherapy. To detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical/analytical assays.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood samples for the analysis of sildenafil in plasma | To detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical/analytical assays. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2030-03-01
- Completion
- 2030-12-01
- First posted
- 2025-01-28
- Last updated
- 2025-01-28
Source: ClinicalTrials.gov record NCT06797479. Inclusion in this directory is not an endorsement.